The complete history of GLP-1 drugs — from 1902 incretin research to exenatide (2005), Victoza (2010), Ozempic (2017), Rybelsus (2019), Wegovy (2021), Mounjaro (2022), Zepbound (2023), and pipeline candidates retatrutide and orforglipron — with where PlexusDx Semaglutide, Tirzepatide, Microdose, and GLP-Squared protocols fit in 2026.

Compare the 2026 best Foundayo (orforglipron) providers — Ro, Found, Form Health, Sesame Care, Weight Watchers Med+, and LillyDirect — and see where the PlexusDx Weight Management Protocols fit as a cash-pay, genetics-informed alternative when insurance excludes weight-loss drugs.

Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($209/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129–$509/mo) compare for someone who needs an option today rather than in 2028.

The honest list of GLP-1 options under $200/mo in April 2026 is much shorter than the ads suggest. PlexusDx Microdose GLP-1 Protocol at $129/mo flat is the lowest under-$200 option in this comparison, with PlexusDx Semaglutide Injection at $179/mo entry tier as the lowest weekly compounded semaglutide path. FDA-approved Foundayo and the Wegovy pill start at $149/mo at lower doses but escalate with dose; most other “$199 GLP-1” ads are first-month-only promos that jump to $249–$349 on refill.

Foundayo's $149 headline is a one-month starter price — the real cash-pay year runs $3,338–$3,738 once you escalate. Compare PlexusDx Microdose GLP-1 ($129/mo flat), Semaglutide Oral ($209+/mo), and Tirzepatide Oral ($229+/mo) on annualized cost.

Foundayo costs $25/month with covered commercial insurance, $50/month on the Medicare GLP-1 Bridge, or $149–$349/month self-pay through LillyDirect. Most commercial plans don't cover GLP-1s for weight loss in 2026. Compare cash-pay PlexusDx Weight Management Protocols — Microdose at $129/mo flat, Semaglutide Injection $179–$229/mo, Tirzepatide Injection $229–$309/mo — with no membership fee.

Eden vs Ro vs PlexusDx for cash-pay GLP-1 weight loss in 2026: real annualized cost math on Eden’s $129–$329/mo all-inclusive compounded plans, Ro’s $149/mo membership plus FDA-approved branded medication (Wegovy, Zepbound, Ozempic, Foundayo), and PlexusDx Weight Management Protocols from $129/mo — with the Precision Peptide Genetic Test as a $99 add-on so dosing is anchored to GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants before week one.

How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

Are GLP-1 pills safe? Four are FDA-approved in 2026 (Rybelsus, Ozempic tablets, Wegovy tablet, Foundayo). Patient-specific compounded oral GLP-1s through licensed pharmacies are a separate lawful category. No-prescription drops and gummies aren't legitimate. Here's the safety framework, the boxed-warning context, and where PlexusDx oral protocols fit.